Pharmacovigilance, pharmacogenetics and poisoning by Doggrell, Sheila
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Doggrell, Sheila
(2017)
Pharmacovigilance, pharmacogenetics and poisoning.
In Pharmacology in One Semester [Version 4].
This file was downloaded from: https://eprints.qut.edu.au/110694/
c© 2017 the Author
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
5. 
PHARMACOVIGILANCE AND PHARMACOGENETICS 
Sheila A Doggrell 
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, 
Gardens Point, GPO Box 2434, QLD 4001, Australia 
Phone +61 7 38705741 Fax +61 7 31381534 Email sheila.doggrell@qut.edu.au 
Reviewer: Tina Hinton, University of Sydney 
Key words: pharmacovigilance, adverse drug effects, adverse drug interactions, 
therapeutic drug monitoring, introduction to pharmacogenetics; enzymes, receptor, ion 
channel 
Contents 
5.1 Pharmacovigilance 
5.1.1 Adverse drug effects 
5.1.1.1 Types 
5.1.1.2 Monitoring of adverse effects 
5.1.2 Adverse drug interactions 
5.2.1.1 Pharmacokinetic 
5.2.1.2 Pharmacodynamic 
5.1.3 Therapeutic drug monitoring 
5.2. Introduction to pharmacogenetics 
5.2.1 Enzymes 
5.2.2 Receptor 
5.2.3 Ion channel 
5.1 Pharmacovigilance 
Pharmacovigilance is the part of pharmacology that relates to the detection, assessment, 
understanding, and prevention of adverse drug effects and adverse drug interactions.  Initially 
we will consider adverse drug effects and their monitoring, then discuss pharmacodynamic 
and pharmacokinetic examples of adverse drug interactions, and finally discuss therapeutic 
drug monitoring.  It is not possible to discuss all the adverse drug effects or adverse drug 
interactions.  This chapter is just an introduction to pharmacovigilance.  A good source of 
information about adverse drug effects and adverse drug interactions is the Australian 
Medicines Handbook, and an alternative is MIMS.  When adverse drug effects or adverse 
drug interactions have been identified, the ideal solution (if possible), is to avoid the drug or 
drug combination. 
5.1.1 Adverse drug effects 
Adverse drug effects are also known as adverse drug reactions, or side effects of drugs.  The 
World Health Organization (WHO) definition for this is “a response to a drug that is noxious 
and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or 
therapy of disease, or for modification of physiological function”.  This means that for the 
same plasma concentrations, both beneficial and adverse effects may be observed. 
5.1.1.1 Types 
Adverse drug effects have been classified as 3 types; A, B, and C.  A is for Augmentation.  
These side effects are extensions of the drug actions.  This can be because the same binding 
site underlies beneficial and adverse effects of the drug.  For instance, digoxin is used to 
increase the force of the heart beat in people with heart failure.  Digoxin is a Na
+
K
+
-ATPase
inhibitor.  Inhibition of the cardiac Na
+
K
+
-ATPase produces both the beneficial effect
(increased heart force) and adverse effects (cardiac arrhythmias) of digoxin on the heart.  In 
addition, Na
+
K
+
-ATPase is present in all cells.  Inhibition by digoxin of Na
+
K
+
-ATPase in
non-cardiac cells for can cause other adverse effects, such as blurred vision and visual 
disturbances. 
Another example of Type A adverse effects is when drugs that show limited selectivity for a 
binding site cause a beneficial action at their target binding site but an adverse effect at 
another binding site.  For example, atenolol is a selective β1-adrenoceptor antagonist that has 
a beneficial effect (antihypertensive) by blocking the cardiac β1-adrenoceptor to decrease 
heart rate and force.  However, as atenolol is only selective, not specific, for β1-
adrenoceptors, this means that atenolol will also have some effect at β2-adrenoceptors.  β2-
adrenoceptors mediate bronchodilation and some metabolism relating to glucose.  The β2-
adrenoceptor blocking action of atenolol is such that it is contraindicated (not to be used) in 
asthmatics. 
In type B adverse effects, the B is for Bizarre or idiosyncratic, adverse effects.  For these 
adverse effects, we do not know what the exact mechanism is.  Type B adverse effects 
include allergy.  As drugs are foreign to the body, it is not surprising that allergic reactions to 
drugs are common.  Drug allergy occurs when the body forms antibodies to a particular 
drug, causing an immune response when the person is re-exposed to a drug.  Thus, the 
allergic response is small on first exposure, but can be large on subsequent exposure.  The 
reason for asking new patients “Are you allergic to any drugs?” is to avoid major allergic 
responses.  People who are allergic to the penicillins develop a rash on first exposure. In 
addition, on repeated exposure, people allergic to penicillin develop angioedema (marked 
swelling of the lips, tongue, and face) and anaphylaxis (respiratory distress, hypotension, 
unconsciousness). 
In type C adverse effects, the C is for Continuous.   These adverse effects are a consequence 
of continuous (long term) use of drug.  An example is with the continuous use of some of the 
older drugs for schizophrenia, such as haloperidol.  Schizophrenia is an ongoing condition 
requiring continuous medication.  However, the long term use of haloperidol can lead to 
tardive dyskinesia.  Tardive dyskinesia is uncontrollable lip smacking, tongue darting, 
constant chewing movements, and tics.  Some people also have jerky, uncontrolled 
movements of arms and legs. 
5.1.1.2 Monitoring of adverse effects 
The adverse effects of drugs are monitored throughout clinical development, in Phase I, II, 
and III clinical trials.  Phase IV of clinical trialling is post-marketing surveillance.  The 
Therapeutic Goods Administration (TGA) regulates Australia’s medicines, medical devices, 
blood, tissues, and chemicals.  In addition, the TGA has an Adverse Drug Reactions 
Advisory Committee (ADRAC), which is responsible for monitoring the adverse effects of 
drugs when they are widely available (Phase IV post-marketing surveillance).  ADRAC relies 
on anecdotal reporting; Mrs Smith took drug A and developed a rash, i.e where there is no 
direct evidence of a link, and the finding could be coincidental.   However, if lots of reports 
come in that drug A causes a rash, the evidence begins to mount.  ADRAC relies on receiving 
voluntary reports from health professionals, which they monitor.  If they think that the 
evidence linking a drug to an adverse effect is substantial, ADRAC may ask for intensive 
adverse event monitoring for that particular drug.  ADRAC reports its findings in the 
Australian Adverse Drug Reactions Bulletin. 
As a health professional, how do you tell whether a reaction is an adverse reaction of a drug?  
There are two general questions to ask the patient.  First, does the reaction get worse with 
increasing doses of the drug?  Most adverse effects of drugs are dose related – the more you 
take, the worse it gets.  If this is the case, it indicates an adverse effect.  Secondly, does the 
reaction go away when the drug is stopped?  Many adverse effects are reversible on removing 
the drug.  If this is the case, it also indicates an adverse effect of the drug. 
5.1.2 Adverse drug interactions 
The second part of Pharmacovigilance is adverse drug interactions.  These can be between a 
prescription drug and a prescription drug or between a prescription drug and a 
complementary or alternative drug.  There are numerous drug interactions, and many of these 
are listed in the Australian Medicines Handbook.  These interactions can be 
pharmacodynamic or pharmacokinetic, and examples of each of these follow. 
5.1.2.1 Pharmacodynamic interactions 
An example of a pharmacodynamic interaction is considered.  Atherosclerosis is usually the 
underlying cause of angina (coronary artery disease) and erectile dysfunction.  Men who 
develop atherosclerosis often have angina and erectile dysfunction.  Nitroglycerin is used to 
relieve or prevent attacks of angina.  Sildenafil (Viagra) is used to treat erectile dysfunction.  
Nitroglycerin acts by mimicking endogenous nitric oxide to stimulate the enzyme guanylate 
cyclase to convert GTP to cGMP, which after a few more steps leads to vasodilation to 
relieve the angina (Figure 5.1).  There is only a small decrease in blood pressure with 
nitroglycerin.   
Figure 5.1 Pharmacodynamic drug interaction (Copyright QUT, Sheila Doggrell) 
Normally, erectile function is mediated by endogenous nitric oxide that stimulates the 
guanylate cyclase to increase the levels of cGMP in the corpus carvenosum, which produces 
relaxation, and blood rushes in to cause penile erection.  The effects of cGMP are short-lived 
as it is rapidly inactivated by the enzyme phosphodiesterase V.  When men take nitroglycerin 
for angina and sildenafil for erectile dysfunction, the sildenafil will inhibit phosphodiesterase 
V in the corpus carvenosum and blood vessels to increase the effect of nitroglycerin (Figure 
5.1).  Thus, the effects of nitroglycerin are increased, and there is a large decrease in blood 
pressure with postural hypotension (dizziness and fainting when standing up).  As a result of 
this interaction, sildenafil is contraindicated in men taking nitroglycerin. 
5.1.2.2 Pharmacokinetic interactions 
The enzyme CYP3A4 metabolises 50% of all drugs, and this is source of many drug 
interactions.  The anti-fungal drug ketoconazole inhibits CYP3A4, and this increases plasma 
levels of drugs metabolised by CYP3A4, of which there are many.  For instance, sildenafil 
(Viagra) is metabolised by CYP3A4.  The combination of ketoconazole and sildenafil leads 
to increased levels of sildenafil.  Lower doses of sildenafil are used in men taking 
ketoconazole.  
5.1.3 Therapeutic drug monitoring 
It is obvious that it will be expensive to monitor the levels of drugs by taking blood samples, 
and detecting the levels of drugs in them.  Therapeutic drug monitoring is usually not needed 
if the toxic levels are above the therapeutic concentrations (Figure 5.2). However therapeutic 
drug monitoring may be needed if toxic levels are similar or overlap therapeutic 
concentrations (Figure 5.2).   
Figure 5.2 Therapeutic drug monitoring (Copyright QUT, Sheila Doggrell) 
In practice, therapeutic drug monitoring is required for a number of drugs including the anti-
epileptic, phenytoin.  Therapeutic drug monitoring is used early in treatment with phenytoin 
to find dose that gives therapeutic effect.  Phenytoin is being given to prevent seizures.  If a 
seizure occurs, it may indicate the concentration of phenytoin in the plasma is below the 
therapeutic dose.  Thus, therapeutic drug monitoring of phenytoin commonly occurs after a 
seizure.  Finally, the levels of phenytoin are measured after a change of dose.  
Another use of therapeutic drug monitoring is in poisoning to determine the treatment 
required, and this occurs with paracetamol overdose.  If levels are above a certain standard, 
treatment of the overdosage is needed to prevent liver toxicity.  This treatment is discussed in 
eChapter 6.  
5.2 Introduction to pharmacogenetics 
Pharmacogenetics, or pharmacogenomics as it is also known, is the study of the genetic basis 
for variation in drug response.  These genetic variations are often due to polymorphism, 
which is a variation in the DNA sequence that is present at a frequency of 1% or greater in a 
population.  Polymorphisms differ within human populations e.g. Caucasians, Chinese. These 
polymorphisms can be in enzymes, receptors, ion channels etc, and some examples are 
discussed below. For most polymorphisms, functional information is not available, as the 
study of pharmacogenetics is its infancy.  The ultimate goal of pharmacogenetics is to 
individualise drug treatments on the basis of individual genetics.   
5.2.1 Enzymes 
The example of a polymorphism in an enzyme is with CYP2D6.  About 15-25% of all drugs 
are substrates for this enzyme.   For instance, haloperidol is metabolised by CYP2D6.  With 
polymorphisms of CYP2D6 gene, 5-10% of people have slow metabolism of these drugs.  
The people who are slow metabolisers are likely to have higher plasma levels of drugs 
metabolised by CYP2D6, and more likely to have toxic effects.  Thus, toxicity to haloperidol 
(e.g. tardive dyskinesia) is likely to be more common in slow metabolisers. 
With some forms of the polymorphism, the people do not metabolise the drugs normally 
metabolised by this enzyme.  For instance, the conversion of codeine to morphine, which is 
responsible for the analgesic effect of codeine, requires CYP2D6.  Polymorphism in CYP2D6 
leads to 10% of Caucasians not being able to convert codeine to morphine.  In these 10%, 
there is a lack of efficacy of codeine, i.e. it does not have a sufficient analgesic effect. 
5.2.2 Receptors 
Polymorphisms are not always associated with loss of activity.  This is shown in the example 
of the receptor polymorphism; epidermal growth factor receptors.  Epidermal growth 
factor receptors (EGFR) are from the receptor tyrosine kinase (TK) family.  EGFR are 
overexpressed in many cancers, and promote the growth of the cancer (Figure 5.3).  
Figure 5.3 Epidermal growth factor receptor (R) and tyrosine kinase (TK) (Copyright QUT, 
Sheila Doggrell) 
Gefitinib inhibits EGFR-tyrosine kinase, and is used in the treatment of some cancers.  There 
is a subset of patients who respond very well (and much better than most patients) to 
gefitinib.  This subset of patients has a polymorphism in their EGFR-tyrosine kinase. 
Gefitinib is a more potent inhibitor of the polymorphism than the wild-type (normal) 
EGFR-tyrosine kinase.  Thus, there is a better response to gefitinib in patients with this 
polymorphism. 
5.2.3 Ion channels 
An example of an ion channel polymorphism is the HERG channel, a potassium channel on 
the heart.  On the electrocardiogram (ECG), the QT interval is a measure of ventricular 
repolarisation (relaxation of heart prior to new beat) (Figure 5.4). 
Figure 5.4 Electrocardiogram (ECG) showing QT interval 
 The “Long QT syndrome” is associated prolonged relaxation of the heart, such that the heart 
may not be fully relaxed and ready to beat again.  This leads to syncope (temporary loss of 
consciousness and posture) and cardiac arrhythmia/sudden death.  This polymorphism is in a 
particular cardiac potassium channel: the HERG channel and can lead to sudden death in 
young people.  On the cardiac potential, the “Long QT syndrome” represents prolonged 
repolarisation (Figure 5.5). 
Figure 5.5 Ventricular action potential and ‘Long QT Syndrome’ (Copyright QUT, Sheila 
Doggrell) 
In addition, several drugs have been shown to prolong the QT interval by blocking the 
HERG, and this leads to an increased risk of cardiac arrhythmias and sudden death.  Several 
commonly used drugs have been withdrawn, as they have been shown to prolong the QT 
interval, e.g. some commonly used antihistamines were withdrawn after they had been on the 
market for several years.  To make sure this does not happen again, in drug development, it is 
now mandatory to test whether a new drug is an inhibitor of HERG channels. 
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6. Poisoning with drugs
All drugs are poisons.  Unfortunately, when medicines are given at higher doses than
recommended, their effects are no longer limited to beneficial with the possibility of some
adverse effects, but become poisonous.  Drugs of abuse are also poisonous.  Poisoning with
drugs is a relatively common reason for attendance at the emergency department of the
hospital.  For example, In Western Australia, there are about 500 hospital admissions for
paracetamol poisoning each year.
6.1 Acute poisoning 
Drugs that can cause poisoning include prescription medicines, OTC (Over-The-Counter) 
medicines (complementary and alternative medicines), alcohol, herbal remedies, and illegal 
drugs. The drugs most commonly associated with fatalities are analgesics (paracetamol and 
aspirin), sedative-hypnotics/antipsychotics, antidepressants, stimulants and street drugs 
(including opioids and cocaine), and cardiovascular drugs (digoxin and Ca
2+
 entry blockers).
In acute poisoning, the general symptoms are nausea, vomiting, dizziness, fitting, drowsiness, 
confusion, coma, and breathing difficulties.  Overdosage is the main reason for poisoning, 
and this overdosage can be accidental or intentional (drug abuse or self-harm). 
6.2 Treatment of poisoning – general 
For most cases of poisoning, there are no specific treatments (Figure 6.1).  The medical care 
is to treat patients not the poison.  Thus, the medical care is of the symptoms, and to support 
the vital functions (breathing, circulation) of the subjects.  For a few poisons, there are 
specific treatments or specific antidotes (Figure 6.1).   
 
Figure 6.1 Treatment of poisoning (Copyright QUT, Sheila Doggrell) 
 
After promptly, maintaining vital functions, especially if their impairment is imminent, other 
treatments can be considered.  The goals of this treatment is to keep concentration of 
drug/poison in crucial tissues as low as possible by preventing absorption and enhancing 
elimination, as this will obviously limit the effects of the poison.  The second goal is to 
combat the pharmacological and toxicological effects at the effector site.   This is especially 
important when it is not possible to get rid of the poison quickly.  Examples of ways to 
prevent absorption, enhance elimination, and to combat the pharmacological and 
toxicological effects are now discussed. 
 
 6.3 Preventing absorption 
The standard treatment of poisoning used to be to make the patient sick (emesis).  However, 
emesis with syrup of ipecac is now rarely used.  When used soon after the intake of certain 
drugs, emesis can be useful, but it is often difficult to ascertain when the poison was taken 
and hence how much poison is still in the stomach. 
 
In several situations, emesis can do more harm than good.  For instance, if the patient 
becomes comatose, emesis can cause aspiration of the gastric contents.  Similarly, if the 
patient is delirious, aspiration can occur.  Aspiration is when the contents of the stomach are 
delivered to the lung, and can be fatal.  Also, if the patient has ingested a central stimulant, 
and is delirious or has hallucinations, the further stimulation associated with vomiting may 
precipitate convulsions. 
 
Syrup of ipecac is derived from a plant source, and is available on prescription or OTC 
(Over-The-Counter).  It has both a local irritant effect on enteric tract and stimulates the 
chemoreceptor trigger zone (CTZ) or emetic centre in the area postrema of the medulla to 
induce emesis.  Syrup of ipecac is indicated when it can be administered to conscious, alert 
patients within 60 minutes of poisoning, and produces vomiting in 15-30 minutes 
 
In addition to emesis, there are two other ways to limit drug absorption.  The first is gastric 
lavage, which is restricted to patients who have taken a life-threatening amount of drug 
within the last 60 min.  For gastric lavage, a tube and large syringe are required.  The 
contents of the stomach are aspirated (sucked up), and then the stomach is lavaged (washed) 
with saline. 
 
The second alternative to emesis is activated charcoal. Activated charcoal adsorbs many 
drugs preventing their absorption and toxicity.  Activated charcoal, does not need to be 
removed artificially, nature can takes its course.  The use of activated charcoal has increased 
recently.  It is indicated for life-threatening amounts of the anti-epileptic drug 
carbamazepine.  
6.4 Enhancing elimination 
The first example of a drug that it is possible to enhance elimination is paracetamol.  A 
minor metabolite of paracetamol NAPQI is extremely toxic to the liver.  Normally most of 
the paracetamol is conjugated and excreted (Figure 6.1).  However, with high poisonous 
levels of paracetamol, the glutathione (GSH) becomes depleted, and NAPQI levels increase.  
N-Acetylcysteine provides a source of GSH to promote the elimination of NAPQI. N-
Acetylcysteine may also combine with NAPQI to reduce the toxicity to this compound, 
and hence to paracetamol (Figure 6.1).
Figure 6.1 Promoting elimination of NAPQI (Copyright QUT, Sheila Doggrell) 
Another way to promote the elimination of drugs is to increase their ionisation, as ionised 
drugs are readily excreted.  For instance, aspirin is a weak acid and is readily reabsorbed 
from kidney tubule.  Thus, aspirin is recycled and remains poisonous.  Urine alkalinization 
with sodium bicarbonate increases the ionization of aspirin, and ionized aspirin is readily 
eliminated.   The enhanced elimination of aspirin reduces its toxicity.   
6.5 Combating pharmacological and toxicological effects 
There are a number of ways of combating pharmacological and toxicological effects of drugs.  
For instance, as discussed in Section 3.5, hemodialysis (cleaning of the blood) can be used to 
remove drugs with low volume of distribution e.g. heparin.  This is because drugs with a low 
volume of distribution are largely confined to the plasma and can be removed by 
heamodialysis.  Drugs with high volume of distribution e.g. the antidepressant nortriptyline, 
and the lipid soluble drugs, cannot be removed with haemodialysis.  
Another approach is competitive reversible antagonism.  For example, naloxone is a 
competitive reversible antagonist at opioid μ receptors, which are the receptors that 
morphine stimulates.  Morphine stimulates opioid μ receptors to be analgesic.  With high 
doses of morphine, the stimulation of opioid μ receptors can cause excessive respiratory 
depression.  The opioid μ receptor competitive reversible antagonist naloxone can be used to 
overcome excessive respiratory depression with morphine. 
 Another example of competitive reversible antagonism is the muscarinic receptor antagonist 
atropine which is used to overcome excessive stimulation of cholinergic muscarinic 
receptors be acetylcholine.  Excessive neostigmine and other acetylcholinesterase inhibitors 
(e.g. Organophosphate pesticides) increase the levels of acetylcholine in the synapse, and the 
acetylcholine stimulates its receptors.  The excessive stimulation of cholinergic muscarinic 
receptors leads effects which mimic activity of the parasympathetic nervous system, and are 
diarrhea, urination, miosis (constricted pupils), bronchospasm, emesis, lacrimation, 
salivation, bradycardia and hypotension. The muscarinic receptor competitive reversible 
antagonist atropine can be used to overcome these effects of excessive acetylcholine at its 
receptor.  
For some poisons, specific antidotes have been developed.  Certain calcium channel blockers 
(e.g. Amlodipine) are used in the treatment of hypertension, and other calcium channel 
blockers (e.g. Verapamil) are used in treatment of cardiac arrhythmias. Too much 
amlodipine can lead to hypotension, whereas too much verapamil can lead to bradycardia 
and/or heart block.  The specific antidote to calcium channel blocker poisoning is calcium 
gluconate.  Increasing the concentration of calcium at the channel, with calcium from calcium 
gluconate, overcomes the effect of blocking the channel with amlodipine or verapamil.  
Another example of a specific antidote is for life-threatening digoxin intoxication, anti-
digoxin immunotherapy can be used to combine with the digoxin and inactivate it.  Digoxin 
is used in the treatment of heart failure.  Digoxin has a low therapeutic index (overlap of 
therapeutic and toxic levels).  Toxicity with digoxin includes life threatening cardiac 
arrhythmias.  In life-threatening digoxin intoxication, anti-digoxin immunotherapy is used.  
The anti-digoxin immunotherapy combines with digoxin to inactivate it  
Finally, chemical antagonism can be used to combat toxicological effects.  The best known 
example of chemical antagonist is to heparin.  Thus, heparin induced life-threatening 
hemorrhage can be overcome with chemical antagonism.  Heparin is strongly acidic.  
Protamine sulphate is strongly basic.  Heparin and protamine combine and the combined 
product is inactive.   
